Forxiga debuts in India at fraction of global prices
This article was originally published in Scrip
Executive Summary
The Indian diabetes segment continues to buzz with action. Close on the heels of going through with a second brand plan for saxagliptin, AstraZeneca Pharma has launched Forxiga (dapaglifozin), for type 2 diabetes, on the Indian market at a fraction of international prices.
You may also be interested in...
IP Divisions In Indian Courts: Will Pharma See Expediated Adjudication?
A second court in India establishes an intellectual property division to consider IPR matters and notifies rules following the dissolution of the Intellectual Property Appellate Board in 2021. Legal experts outline what that may mean for the efficiency and quality of IPR adjudications.
IP Divisions In Indian Courts: Will Pharma See Expediated Adjudication?
A second court in India establishes an intellectual property division to consider IPR matters and notifies rules following the dissolution of the Intellectual Property Appellate Board in 2021. Legal experts outline what that may mean for the efficiency and quality of IPR adjudications.
Jardiance, Trajenta Wins: Boehringer Takes Rough With Smooth In India
Boehringer Ingelheim tackles infringement activity pertaining to Trajenta and Jardiance in India, at least for now, but more action appears to be in the wings. The private German group remains confident that Jardiance will retain its preferred treatment choice status in the country for type 2 diabetes - but can the blockbuster therapy shake up the heart failure segment as well?